9.40
22.88%
+1.75
IGM Biosciences Inc stock is currently priced at $9.40, with a 24-hour trading volume of 468.92K.
It has seen a +22.88% increased in the last 24 hours and a +8.29% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.27 pivot point. If it approaches the $9.51 resistance level, significant changes may occur.
Previous Close:
$7.65
Open:
$7.74
24h Volume:
468.92K
Market Cap:
$552.59M
Revenue:
$2.13M
Net Income/Loss:
$-246.42M
P/E Ratio:
-1.7837
EPS:
-5.27
Net Cash Flow:
$-204.61M
1W Performance:
+30.56%
1M Performance:
+8.29%
6M Performance:
+112.67%
1Y Performance:
-13.60%
IGM Biosciences Inc Stock (IGMS) Company Profile
Name
IGM Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 East Middlefield Road, Mountain View
IGM Biosciences Inc Stock (IGMS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-09-22 | Resumed | Jefferies | Buy |
Oct-17-22 | Initiated | JP Morgan | Neutral |
Aug-29-22 | Initiated | BofA Securities | Buy |
Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
Aug-26-21 | Initiated | Morgan Stanley | Overweight |
Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
Jul-17-20 | Initiated | Robert W. Baird | Outperform |
Jul-01-20 | Initiated | H.C. Wainwright | Buy |
May-28-20 | Initiated | SunTrust | Buy |
Apr-22-20 | Initiated | Wedbush | Outperform |
Oct-14-19 | Initiated | Guggenheim | Buy |
Oct-14-19 | Initiated | Jefferies | Buy |
Oct-14-19 | Initiated | Piper Jaffray | Overweight |
Oct-14-19 | Initiated | Stifel | Buy |
View All
IGM Biosciences Inc Stock (IGMS) Latest News
What 5 Analyst Ratings Have To Say About IGM Biosciences
Benzinga
IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire Inc.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
GlobeNewswire Inc.
Where IGM Biosciences Stands With Analysts
Benzinga
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
IGM Biosciences Inc Stock (IGMS) Financials Data
IGM Biosciences Inc (IGMS) Revenue 2024
IGMS reported a revenue (TTM) of $2.13 million for the quarter ending December 31, 2023.
IGM Biosciences Inc (IGMS) Net Income 2024
IGMS net income (TTM) was -$246.42 million for the quarter ending December 31, 2023, a -11.45% decrease year-over-year.
IGM Biosciences Inc (IGMS) Cash Flow 2024
IGMS recorded a free cash flow (TTM) of -$204.61 million for the quarter ending December 31, 2023, a -1,174% decrease year-over-year.
IGM Biosciences Inc (IGMS) Earnings per Share 2024
IGMS earnings per share (TTM) was -$4.78 for the quarter ending December 31, 2023, a +10.99% growth year-over-year.
IGM Biosciences Inc Stock (IGMS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP | Director |
Mar 27 '24 |
Buy |
9.24 |
27,844 |
257,170 |
3,664,073 |
BAKER BROS. ADVISORS LP | Director |
Mar 26 '24 |
Buy |
8.26 |
270,000 |
2,230,767 |
3,638,533 |
Schwarzer Fred | CEO AND PRESIDENT |
Mar 14 '24 |
Sale |
10.17 |
4,182 |
42,533 |
216,651 |
Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 14 '24 |
Sale |
10.17 |
2,543 |
25,864 |
90,418 |
Takimoto Chris H | CHIEF MEDICAL OFFICER |
Mar 14 '24 |
Sale |
10.17 |
2,535 |
25,782 |
94,388 |
Keyt Bruce | CHIEF SCIENTIFIC OFFICER |
Mar 14 '24 |
Sale |
10.17 |
1,844 |
18,754 |
171,856 |
Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Mar 14 '24 |
Sale |
10.17 |
1,578 |
16,049 |
61,006 |
Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
Mar 14 '24 |
Sale |
10.17 |
464 |
4,719 |
26,507 |
Schwarzer Fred | CEO AND PRESIDENT |
Mar 13 '24 |
Sale |
9.88 |
4,765 |
47,055 |
220,833 |
Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 13 '24 |
Sale |
9.88 |
2,897 |
28,608 |
92,961 |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Cap:
|
Volume (24h):